Abstract: Objective To observe the effects and influence factors of artificial liver support system (ALSS)
combined antiviral therapy on patients with HBV-related acute-on-chronic liver failure (HBV-ACLF).
Methods Total of 1912 HBV-ACLF patients from January 1st, 2010 to December 31st, 2014 in Public
Health Clinical Center of Chengdu were enrolled and divided into control group (967 cases, received medical
treatment including antiviral therapy) and treatment group (945 cases, received medical treatment and ALSS).
The biochemical criterions including liver function, coagulation function and blood ammonia of both groups
were detected, the influential factors were observed and analyzed by Logistic regression. Results The indexes
of hepatic function, coagulation function and blood ammonia improved after treatment in both groups, and
the treatment group were more obvious. The effective rate, clinical improvement or cure rate and survival
rate in 12 weeks in treatment group (62.8%, 59.4% and 56.5%, respectively) were much better than those of
control group (15.9%, 31.5% and 30.0%, respectively; χ 2 = 215.12, 197.93, 176.45, respectively, P =0.000）.
Some patients had adverse reactions, including rash (7.0%), transient decreases in blood pressure (1.6%) and
hemorrhage (0.2%), and no serious adverse reaction occurred. The effectiveness in HBV-ACLF patients had a
close relationship with HBV DNA load, disease stage, complications, ALSS and antiviral therapy（P = 0.006,0.008, 0.016, 0.024, 0.000, respectively）. Conclusions ALSS combined antiviral therapy can effectively
release the symptoms and can improve biochemical indexes or survival rates of patients with HBV-ACLF.
As the patients are confirmed to be HBV-ACLF and the conditions are permited, ALSS combined antiviral
therapy should be performed in order to reduce the fatality.